A recent study published in JAMA compared the effectiveness of two medications, methadone and buprenorphine/naloxone, for treating opioid use disorder, revealing that patients treated with methadone had a lower rate of treatment discontinuation over 24 months.
A recent study reveals how both disease-specific and general factors influence cognitive impairment in psychotic disorders, shedding light on the significant cognitive deficits experienced by individuals with schizophrenia, schizoaffective disorder, and bipolar I disorder.
A systematic analysis of 68 studies and 9,525 participants with schizophrenia spectrum disorders found that no antipsychotic significantly outperformed placebo in improving cognitive function. The analysis concludes that standardizing cognitive assessments in clinical trials could enhance result consistency. (Source: JAMA Psychiatry)
Research published in BMC Primary Care finds that only 44% of patients with opioid use disorder in primary care settings adhere to their prescribed buprenorphine treatment, with male sex and unexpected positive opioid toxicology results associated with lower adherence.
People with severe mental illness face over 3 times higher risk of death from respiratory infections, with pneumonia mortality risk increased more than 4-fold compared to the general population.
Alcohol withdrawal syndrome accounted for 9% to 11% of hospitalizations in men aged 30 to 49 and up to 44% in high-risk alcohol users, surpassing other chronic conditions like diabetes and hypertension in those under 60.